IP Library Granted Patent US 8,357,377
Granted Patent B2
US 8,357,377 · App. 10/681,745 · Granted Jan 22, 2013

Cyclodextrin-based materials, compositions and uses related thereto

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,357,377
App. No.
10/681,745
Granted
Jan 22, 2013
Kind
B2
Abstract

This application discloses cyclodextrin-modified materials for carrying drugs and other active agents, such as nucleic acids. Compositions are also disclosed of cyclodextrin-modified materials that release such active agents under controlled conditions. The invention also discloses compositions of cyclodextrin-modified polymer carriers that are coupled to biorecognition molecules for assisting the delivery of drugs to their site of action.

Claims (19)

1. A polymer composition comprising:

a linear biocompatible polymer including a plurality of inclusion hosts,

linking molecules, each linking molecule comprising a PEG moiety and at least two adamantane moieties that form inclusion complexes with the inclusion hosts, and

at least one therapeutic agent,

wherein the linking molecules cross-link the polymer solely through inclusion complexes; and

wherein the therapeutic agent is covalently attached to an adamantane moiety.

2. The polymer composition of claim 1 , wherein the inclusion hosts are cyclodextrin moieties.

3. The polymer composition of claim 1 , wherein the therapeutic agent is a nucleic acid.

4. The polymer composition of claim 3 , wherein the nucleic acid is provided in a delivery system selected from a virus, a polymer, and a liposome.

5. The polymer composition of claim 1 , wherein the therapeutic agent is a protein, a polypeptide, or a small organic molecule.

6. The polymer composition of claim 1 , wherein the therapeutic agent is a protein or polypeptide.

7. The polymer composition of claim 1 , further comprising at least one adjuvant.

8. The polymer composition of claim 1 , further comprising an adjuvant that increases the effectiveness of the therapeutic agent.

9. The polymer of claim 1 , wherein the linking molecules cross-link the polymer intramolecularly.

10. The polymer of claim 1 , wherein the linking molecules cross-link the polymer intermolecularly.

11. The polymer composition of claim 2 , wherein the cyclodextrin moieties are within the polymer chain.

12. The polymer composition of claim 2 , wherein the cyclodextrin moieties are appended to the polymer chain.

13. The polymer composition of claim 1 , wherein the linear biocompatible polymer is biodegradable.

14. The polymer composition of claim 1 , wherein the linking molecule comprises at least three adamantane moieties.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 1, 2009
From: CALANDO PHARMACEUTICALS, INC.
To: CERULEAN PHARMA INC.
Reel/Frame 022892/0529 →
CHANGE OF NAME Recorded Apr 13, 2009
From: INSERT THERAPEUTICS, INC.
To: CALANDO PHARMACEUTICALS, INC.
Reel/Frame 022510/0899 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2004
From: CALIFORNIA TECHNOLOGY PARTNERS, L.P.; J.J. JACOBS ENTERPRISES, LLC
To: INSERT THERAPEUTICS, INC.
Reel/Frame 014763/0969 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2004
From: PUN, SUZIE; BELLOCQ, NATHALIE; DAVIS, MARK
To: INSERT THERAPEUTICS, INC.
Reel/Frame 014273/0910 →